BOSTON & GENEVA–(BUSINESS WIRE)–Neurosterix, a clinical-stage biotechnology company focused on neuropsychiatric disorders, announced the closing of a $105 million Series B.

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.